MLH1

MLH1
National Center for Biotechnology Information, U.S. National Library of Medicine · Public domain · source
Name	MutL homolog 1
Uniprot	P40692
Organism	Human
Length	756 aa

MLH1 MLH1 is a human DNA mismatch repair protein involved in maintenance of genomic stability and correction of replication errors. It participates in heterodimeric complexes that coordinate recognition and repair of base–base mismatches and insertion–deletion loops, with implications for cancer susceptibility and response to chemotherapy. MLH1 activity has been characterized in cellular, biochemical, and genetic studies across model systems and informs clinical diagnostics in oncology and hereditary cancer syndromes.

Function

MLH1 functions as a core component of post-replicative DNA mismatch repair through formation of heterodimers that mediate downstream repair events. In human cells MLH1 heterodimerizes to form complexes that recruit exonucleases and coordinate strand discrimination during excision and resynthesis, influencing genomic stability, microsatellite integrity, and somatic mutation rates. Loss of MLH1 function leads to elevated mutation burden, microsatellite instability, and altered sensitivity to DNA damaging agents used in oncology, affecting tumorigenesis in colorectal, endometrial, and other epithelial tissues.

Structure and Domains

MLH1 is an approximately 756–amino acid protein composed of an N‑terminal ATPase domain and a C‑terminal domain responsible for dimerization and protein–protein interactions. The N‑terminal domain contains conserved motifs characteristic of the GHKL ATPase family and coordinates nucleotide binding and hydrolysis that modulate conformational states. The C‑terminal domain mediates interaction interfaces with partner proteins and contains surfaces essential for heterodimer formation; structural studies have resolved domain architecture by X‑ray crystallography and cryo‑EM, enabling mapping of pathogenic variants to functional regions.

Clinical Significance

Germline pathogenic variants in MLH1 are a major cause of hereditary cancer predisposition syndromes characterized by high risk of colorectal and extracolonic tumors; clinical management incorporates genetic testing, surveillance, and risk‑reducing strategies. Loss or epigenetic silencing of MLH1 contributes to sporadic microsatellite instability (MSI) in tumors, guiding selection of immunotherapy and cytotoxic regimens. MLH1 status is a biomarker used in diagnostic algorithms and prognostic models, influencing decisions in oncology practice and clinical trials assessing targeted therapies and checkpoint blockade.

Genetics and Regulation

The MLH1 locus is subject to germline variation, somatic mutation, and epigenetic regulation, including promoter hypermethylation that can silence transcription in tumors. Germline pathogenic variants are cataloged in clinical registries and inform cascade testing in families with hereditary cancer syndromes. Transcriptional regulation involves promoter elements responsive to developmental and stress signals, and post‑translational modifications modulate MLH1 stability, localization, and interaction capacity. Allelic variants with partial function produce variable phenotypes ranging from attenuated cancer risk to early‑onset syndromes.

Interactions

MLH1 participates in a network of protein–protein interactions that orchestrate mismatch repair and checkpoint functions. Partners include heterodimeric partners that define repair specificity, nucleases that execute excision, mismatch sensors that trigger recruitment, and cell‑cycle regulators that coordinate repair with replication. These interactions have been mapped by biochemical reconstitution, affinity purification, and genetic epistasis analyses, revealing modular assemblies that determine repair outcome and crosstalk with pathways controlling DNA damage response and apoptosis.

Model Organisms and Experimental Studies

Functional characterization of MLH1 has relied on yeast genetics, murine knockout models, and cellular complementation assays that recapitulate mismatch repair deficiency. Studies in model organisms have elucidated conserved roles in genome maintenance, the consequences of loss for tumorigenesis, and modifier effects of genetic background. Experimental systems, including engineered cell lines and animal models, underpin translational research evaluating therapeutic vulnerabilities, synthetic lethality, and biomarker development for precision oncology.

Category:DNA repair proteins